NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT06308575 2025-01-10
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03164694 2024-12-10
APPEAL
Sun Yat-sen University
Phase 2 Withdrawn
NCT03228043 2024-11-14
Apatinib for Resectable Colorectal Cancer
Nanchong Central Hospital
Phase NA Withdrawn
NCT03190239 2024-02-28
XQonc-007
Xinqiao Hospital of Chongqing
Phase 2 Withdrawn
NCT03792503 2024-02-28
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen
Xinqiao Hospital of Chongqing
Phase 4 Withdrawn
NCT03193814 2024-01-03
XHZL
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Withdrawn
NCT03787251 2022-04-19
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Withdrawn
NCT03104335 2020-05-19
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Peking University People's Hospital
Phase 2 Withdrawn